knowledge -WSS

knowledge

author：knowledge 2025-09-27 15:20:55 - browse：28

Has PhRMA lost its fangs? Are 11th-hour changes ominous for clinical trials? And what’s next in pain medicine?

We cover all that and more this week on “The Readout LOUD,” STAT’s biotech podcast. The pharmaceutical industry, in court and in Congress, is working to water down legislation that will let Medicare negotiate certain drug prices. STAT Washington correspondent Rachel Cohrs joins us to explain the industry’s struggle to make headway — and how it factors into the 2024 election. We also discuss the latest news in the life sciences, including a twist in the future of Alnylam Pharmaceuticals, competition to Vertex Pharmaceuticals’ pain drug, and Gilead Sciences’ latest acquisition.

For more on what we cover, here’s all of Rachel’s coverage; here’s more on Vertex’s competition; here’s the news on Gilead; here’s where you can find episodes of Color Code; here’s where you can subscribe to the First Opinion Podcast; and here’s where you can subscribe to our biotech newsletter, The Readout.

Be sure to sign up on Apple Podcasts, Spotify, Stitcher, TuneIn, or wherever you get your podcasts.

And if you have any feedback for us — topics to cover, guests to invite, vocal tics to cease — you can email [email protected].

Previous article： Heart attack and stroke risk calculators need revising
Next article： UnitedHealth, in a surprise, takes aim at Steward’s physician group

explore

WSS

Medicare Advantage 2025 payments will dip, Biden administration says

Readout Newsletter: Cytokinetics and Novartis' starcrossed tale

Nonprofit, backed by Microsoft, to certify AI tools in health care

At JPM 2024, hospital systems pitch financial strength to investors

Drug companies' payments and gifts affect physicians' prescribing

JPM 2024 Review: Hope for the XBI, deals from J&J, Merck, GSK

entertainment

knowledge

entertainment

Tori Bowie and the unacceptable rates of Black maternal death

Harvard scientists, with Google, unveil the most detailed brain map ever

Sports medicine is finally prioritizing gender equality

A preacher's new calling: Diversifying neuroscience research

Biden outlines 'new path' to provide student loan relief after Supreme Court rejection

Study suggests new cause of Down syndrome: cells linked to aging

How to save PrEP access — and even expand it

Trial using CRISPR to edit HIV out of cells disappoints

Duchenne breakthrough therapy leaves behind pioneering families

American taxpayers paid $1.8 trillion in health care costs in 2022

Wikipedia

Medicare Advantage coverage denials need scrutiny, senators say

Medicare Advantage coverage denials need scrutiny, senators say

First Opinion on colorectal cancer screening: letter and response

Boston Scientific acquires urology company Axonics for $3.7 billion

Ascension's ugly legal battle over care for poor patients in Texas

Multiple sclerosis has subtypes with different best treatments: study

leisure time

focus

explore

knowledge